There are similarities between rheumatic disease with lung involvement and COVID-19 pneumonia

Williamson, Joseph R.; Black, Louisa; Black, Anna J; Koduri, Gouri; Kelly, Clive

doi:10.1007/s11845-021-02545-y

Cited by 7 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering that some similarities could be found between interstitial lung disease developing after SARS-CoV-2 infection and in some autoimmunological diseases, it is recently hypothesized that immunosuppressive and biologic agents could play a therapeutic role in the treatment of COVID-19 patients [ 82 ]. Similarities between idiopathic pulmonary fibrosis (IPF) and pneumonitis in the course of COVID-19 are also observed; thus, antifibrotic drugs, as used in IPF treatment, are deemed to be used [ 83 , 84 ].…”

Section: Pulmonary Complications Of Covid-19mentioning

confidence: 99%

Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19

Kobusiak−Prokopowicz

Fułek

et al. 2022

Cells

View full text Add to dashboard Cite

Beginning with the various strategies of the SARS-CoV-2 virus to invade our bodies and manifest infection, and ending with the recent long COVID, we are witnessing the evolving course of the disease in addition to the pandemic. Given the partially controlled course of the COVID-19 pandemic, the greatest challenge currently lies in managing the short- and long-term complications of COVID-19. We have assembled current knowledge of the broad spectrum of cardiovascular, pulmonary, and neuropsychiatric sequelae following SARS-CoV-2 infection to understand how these clinical manifestations collectively lead to a severe form of the disease. The ultimate goal would be to better understand these complications and find ways to prevent clinical deterioration.

show abstract

Section: Pulmonary Complications Of Covid-19mentioning

confidence: 99%

Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19

Kobusiak−Prokopowicz

Fułek

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…Coronaviruses use membrane ACE2 receptors to enter human cells. At the same time, ACE2 is also highly expressed in lung cells of patients with RA-related interstitial lung disease (ILD), and patients with RA and ILD are more susceptible to high inflammation and acute lung injury than the general population 17 , 18 . In addition, RA-ILD and COVID-19-infected lung lesions have remarkable similarities in epidemiological, clinical, and immunological characteristics.…”

Section: Discussionmentioning

confidence: 99%

Analysis of related factors for RA flares after SARS-CoV-2 infection: a retrospective study from patient survey

Li,

Zhao,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

SARS-CoV-2 and its variants are widely prevalent worldwide. With frequent secondary and breakthrough infections, immune dysfunction in RA patients, and long-term use of immune preparations, SARS-CoV-2 infection poses a significant challenge to patients and rheumatologists. Whether SARS-CoV-2 infection causes RA flares and what factors aggravate RA flares are poorly studied. A questionnaire survey was conducted on RA patients infected with SARS-CoV-2 after December 7, 2022, in China through a multicenter and inter-network platform regarding general personal condition, primary disease, comorbidity, SARS-CoV-2 vaccination, viral infection, and impact on the primary disease. A total of 306 RA patients were included in this study, and the patient data were analyzed, in which the general condition of RA patients, medication use before SARS-CoV-2 infection and post-infection typing and manifestations, and medication adjustment did not affect the Flare of RA patients after SARS-CoV-2 infection. The control of disease before SARS-CoV-2 infection (OR = 2.10), RA involving pulmonary lesions (OR = 2.28), and the recovery time of COVID-19 (OR = 2.50) were risk factors for RA flare. RA involving pulmonary lesions, control status of disease before infection, and recovery time of COVID-19 disease are risk factors for RA flare after SARS-CoV-2 infection.

show abstract

“…Новые проблемы диагностики и лечения РА-ИЗЛ возникли в период пандемии COVID-19. Во-первых, поражение легких (по данным КТВР) при РА-ИЗЛ имеет сходные черты с COVID-19-пневмонией [207,208]; во-вторых, у пациентов с РА-ИЗЛ наблюдается тяжелое течение COVID-19 [209][210][211][212], а инфекция SARS-CoV-2 может индуцировать развитие О-РА-ИЗЛ [213,214]. Хотя ГК, ингибиторы ИЛ-6 и ингибиторы JAK широко применяются для лечения COVID-19-ассоциированного гипервоспалительного синдрома [215], данные регистров свидетельствуют о возможном риске инфицирования вирусом SARS-CoV-2 и тяжелого течения COVID-19 у пациентов РА, получающих ГК, ингибиторы JAK и особенно РТМ [216,217].…”

Section: ревматоидный артритunclassified

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology

Насонов

Ananieva²,

Avdeev

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an immune-mediated rheumatic disease (IMRDs) characterized by chronic erosive arthritis and systemic damage to internal organs, leading to early disability and reduced life expectancy in patients. A particularly important place among the systemic manifestations of RA is occupied by interstitial lung diseases (ILD) – the most severe form of pulmonary pathology in RA, defined as RA-ILD, which is pathogenetically associated with risk factors (smoking, etc.) and autoimmune mechanisms underlying RA. RA-ILD is a subtype of RA characterized by a severe course and a poor prognosis и неблагоприятным прогнозом. The review presents new data regarding risk factors and biomarkers for RA-ILD; modern diagnostic capabilities based on the use of functional lung tests, high-resolution computed tomography, ultrasound examination of the lungs. Particular attention is paid to the efficacy and safety of pharmacotherapy, including methotrexate, biologics, JAK inhibitors, and antifibrotic therapy. An algorithm for the pharmacotherapy of RA-ILD has been proposed.

show abstract

There are similarities between rheumatic disease with lung involvement and COVID-19 pneumonia

Cited by 7 publications

References 53 publications

Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19

Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19

Analysis of related factors for RA flares after SARS-CoV-2 infection: a retrospective study from patient survey

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology

Contact Info

Product

Resources

About